Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004151
Status:
COMPLETED
Last Update Posted:
2012-09-24
First Post:
1999-12-10
Brief Title:
Acridine Carboxamide in Treating Patients With Advanced Non-small Cell Lung Cancer
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Advanced Non Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery
PURPOSE Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery
Detailed Description:
OBJECTIVES I Determine the effect of acridine carboxamide on objective response response rate and duration of response in patients with unresectable locally advanced progressive or metastatic non-small cell lung cancer II Determine the toxicities and pharmacokinetics of this regimen in these patients
OUTLINE This is a multicenter study Patients receive acridine carboxamide IV over 24 hours for 5 days Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 6 weeks until disease progression or commencement of another treatment
PROJECTED ACCRUAL A total of 14-25 patients will be accrued for this study
OUTLINE This is a multicenter study Patients receive acridine carboxamide IV over 24 hours for 5 days Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity Patients are followed every 6 weeks until disease progression or commencement of another treatment
PROJECTED ACCRUAL A total of 14-25 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EORTC-16991N | None | None | None |